Ovid Therapeutics Inc.
Ovid Therapeutics is a biopharmaceutical company dedicated to developing targeted small molecule therapies to treat epilepsies and brain conditions. Founded in 2014, the company aims to conquer neurological diseases with courageous science, focusing on innovative mechanisms of action to reduce seizures and improve safety and tolerability. Their pipeline includes clinical-stage programs OV329 and OV888, and preclinical KCC2 activator compounds. Ovid is committed to transforming the lives of individuals with neurological disorders through science-driven and patient-focused approaches.
Industries
Nr. of Employees
small (1-50)
Ovid Therapeutics Inc.
Hudson Commons, 441 9th Avenue, New York, NY 10001
Patents
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US-12285397-B2
View Details
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US-12285397-B2
View DetailsProducts
Selective ROCK2 inhibitor development program
Development of a selective ROCK2-targeting small-molecule program for neurological indications; completed a healthy volunteer Phase 1 study with favorable safety and PK, and subsequently paused initiation of a Phase 2 proof-of-concept study pending evaluation of external competitor data.
KCC2 activator portfolio
A portfolio of direct KCC2 transporter activators developed from an in-licensed library, with both intravenous and oral candidate series intended to restore neuronal chloride homeostasis and reduce hyperexcitability across multiple CNS indications.
GABA-aminotransferase inhibitor program
Development of a next-generation GABA-aminotransferase (GABA-AT) inhibitor program being evaluated for treatment-resistant epilepsies and developmental epileptic encephalopathies, with oral and IV formulation strategies and an ongoing Phase 1 study measuring safety, PK and target engagement biomarkers.
Selective ROCK2 inhibitor development program
Development of a selective ROCK2-targeting small-molecule program for neurological indications; completed a healthy volunteer Phase 1 study with favorable safety and PK, and subsequently paused initiation of a Phase 2 proof-of-concept study pending evaluation of external competitor data.
KCC2 activator portfolio
A portfolio of direct KCC2 transporter activators developed from an in-licensed library, with both intravenous and oral candidate series intended to restore neuronal chloride homeostasis and reduce hyperexcitability across multiple CNS indications.
GABA-aminotransferase inhibitor program
Development of a next-generation GABA-aminotransferase (GABA-AT) inhibitor program being evaluated for treatment-resistant epilepsies and developmental epileptic encephalopathies, with oral and IV formulation strategies and an ongoing Phase 1 study measuring safety, PK and target engagement biomarkers.
Services
Structuring and executing research collaborations, exclusive in-licensing, option agreements and commercial licenses including upfront payments, milestone schedules and tiered royalties; governance through joint development committees.
Engagement, outreach and resource-sharing with patient organizations to inform development priorities and support community needs.
Strategic and operational services to advance early-phase clinical programs, including protocol planning, biomarker selection and trial execution.
Structuring and executing research collaborations, exclusive in-licensing, option agreements and commercial licenses including upfront payments, milestone schedules and tiered royalties; governance through joint development committees.
Engagement, outreach and resource-sharing with patient organizations to inform development priorities and support community needs.
Strategic and operational services to advance early-phase clinical programs, including protocol planning, biomarker selection and trial execution.
Expertise Areas
- Small-molecule CNS drug discovery and medicinal chemistry
- Target-focused platform development for neurological indications
- Preclinical efficacy and proof-of-mechanism studies
- Formulation development for oral and intravenous administration
Key Technologies
- Selective kinase inhibition (ROCK2-targeting)
- KCC2 transporter activation
- GABA-aminotransferase inhibition
- Next-generation small-molecule design using generative AI